NAD World 3.0: the importance of the NMN transporter and eNAMPT in mammalian aging and longevity control

Plain-language summary

Published 2025 in NPJ Aging, this work by Imai SI and collaborators tackles a specific question within science-focused NMN/NAD+ research.

Key findings reported by the authors

• Review article in NPJ Aging (2025) summarising the state of NAD+/NMN/sirtuin science
• Useful synthesis for understanding mechanism and evidence quality
• Cited as reference for NAD+ booster therapeutic claims

What this means for Malaysian buyers

For readers in Malaysia weighing whether to start or continue NMN supplementation, this paper sits at the moderate end of the evidence spectrum. Moderate-tier evidence usually means a small human trial or a well-designed mouse study; helpful for hypothesis-building but not for hard recommendations. Findings here are most directly relevant to science decisions. Our editorial methodology weights human placebo-controlled trials above mouse mechanistic work above review articles.